Subtopic Deep Dive
Valvular Heart Disease Management in Pregnancy
Research Guide
What is Valvular Heart Disease Management in Pregnancy?
Valvular heart disease management in pregnancy involves lesion-specific risk assessment, anticoagulation strategies, and surgical timing for patients with native or prosthetic valves during gestation.
This subtopic addresses maternal and fetal outcomes in pregnant women with valvular heart disease (VHD), emphasizing pre-pregnancy counseling and multidisciplinary care. Key registries like ROPAC and ESC studies report heart failure as the primary complication, occurring in late second trimester or postpartum (Ruys et al., 2013; 245 citations). Over 20 studies from 2001-2020, including high-citation works by Roos-Hesselink et al. (2012; 446 citations) and Elkayam & Bitar (2005; 277 citations), analyze progression of native valves and prosthetic valve thrombosis risks.
Why It Matters
VHD in pregnancy drives preterm delivery, heart failure, and neonatal complications, necessitating updated ESC and AHA guidelines for risk stratification (Roos-Hesselink et al., 2012; Mehta et al., 2020). Ávila et al. (2003; 269 citations) revised historical contraindications, showing safe outcomes with specialized care in 1,000 cases. Elkayam & Bitar (2005) detail mechanical valve anticoagulation balancing thromboembolism and fetal warfarin embryopathy, informing clinical decisions in cardio-obstetrics teams. ROPAC data link VHD-related heart failure to pre-eclampsia, reducing maternal mortality from 1-2% to <1% with protocols (Ruys et al., 2013).
Key Research Challenges
Anticoagulation Balance
Balancing thromboembolism prevention in prosthetic valves against fetal risks from warfarin embryopathy remains unresolved. Elkayam & Bitar (2005; 277 citations) highlight low-molecular-weight heparin inferiority to warfarin for mechanical valves. Recent guidelines lack randomized trials specific to pregnancy.
Lesion-Specific Risk Models
Predicting outcomes for aortic vs. mitral stenosis or regurgitation varies by lesion severity and progression. Roos-Hesselink et al. (2012; 446 citations) from ESC registry show worse outcomes in severe aortic stenosis. Validation studies like Balcı et al. (2014; 245 citations) assess models but note limitations in VHD subsets.
Surgical Timing Optimization
Deciding valve intervention pre-pregnancy, during gestation, or postpartum risks fetal loss versus maternal decompensation. Ruys et al. (2013; 245 citations) report heart failure peaks late pregnancy, complicating timing. Ávila et al. (2003; 269 citations) document surgical needs in 2% of 1,000 cases.
Essential Papers
Outcome of pregnancy in patients with structural or ischaemic heart disease: results of a registry of the European Society of Cardiology
Jolien W. Roos‐Hesselink, Titia P.E. Ruys, Jörg Stein et al. · 2012 · European Heart Journal · 446 citations
The vast majority of patients can go safely through pregnancy and delivery as long as adequate pre-pregnancy evaluation and specialized high-quality care during pregnancy and delivery are available...
Cardiovascular Considerations in Caring for Pregnant Patients: A Scientific Statement From the American Heart Association
Laxmi S. Mehta, Carole A. Warnes, Elisa A. Bradley et al. · 2020 · Circulation · 378 citations
Cardio-obstetrics has emerged as an important multidisciplinary field that requires a team approach to the management of cardiovascular disease during pregnancy. Cardiac conditions during pregnancy...
Valvular Heart Disease and Pregnancy
Uri Elkayam, Fahed Bitar · 2005 · Journal of the American College of Cardiology · 277 citations
Pregnancy in patients with heart disease: Experience with 1,000 cases
Walkíria Samuel Ávila, E Rossi, José Antônio Franchini Ramires et al. · 2003 · Clinical Cardiology · 269 citations
Abstract Background : Previously, the high maternal mortality in cardiac patients who became pregnant prompted the assertion: Women with an abnormal heart should not become pregnant. This long‐stan...
Heart failure in pregnant women with cardiac disease: data from the ROPAC
Titia P.E. Ruys, Jolien W. Roos‐Hesselink, Roger Hall et al. · 2013 · Heart · 245 citations
HF was the most common complication during pregnancy, and occurred typically at the end of the second trimester, or after birth. It was most common in women with cardiomyopathy or pulmonary hyperte...
Prospective validation and assessment of cardiovascular and offspring risk models for pregnant women with congenital heart disease
Ali Balcı, Krystyna M. Sollie-Szarynska, Antoinette G L van der Bijl et al. · 2014 · Heart · 245 citations
Objectives Adequate prepregnancy prediction of maternal cardiovascular and offspring risk is important for counselling and management of pregnancy in women with congenital heart disease (CHD). Ther...
Heart disease and pregnancy
Samuel C. Siu, Jack M Colman · 2001 · Heart · 244 citations
Pregnancy in most women with heart disease has a favourable maternal and fetal outcome. With the exception of patients with Eisenmenger syndrome, pulmonary vascular obstructive disease, and Marfan ...
Reading Guide
Foundational Papers
Start with Roos-Hesselink et al. (2012; 446 citations) for ESC registry outcomes in structural heart disease including VHD; Elkayam & Bitar (2005; 277 citations) for valve-specific physiology; Ávila et al. (2003; 269 citations) for large cohort maternal mortality revisions.
Recent Advances
Mehta et al. (2020; 378 citations) AHA statement on cardio-obstetrics; Balcı et al. (2014; 245 citations) for validated CHD risk models applicable to VHD; Ruys et al. (2013; 245 citations) ROPAC heart failure data.
Core Methods
Prospective registries (ROPAC, ESC), modified WHO risk classification, CARP-II/ZAHARA models, echocardiography for lesion severity, multidisciplinary cardio-obstetric teams (Roos-Hesselink et al., 2012; Mehta et al., 2020).
How PapersFlow Helps You Research Valvular Heart Disease Management in Pregnancy
Discover & Search
Research Agent uses searchPapers and citationGraph on 'valvular heart disease pregnancy ROPAC' to map 50+ papers from Roos-Hesselink et al. (2012; 446 citations), revealing clusters on prosthetic valves. exaSearch uncovers guideline-linked studies; findSimilarPapers expands from Elkayam & Bitar (2005) to Ávila et al. (2003).
Analyze & Verify
Analysis Agent applies readPaperContent to extract ROPAC heart failure rates from Ruys et al. (2013), then verifyResponse with CoVe checks claims against Mehta et al. (2020). runPythonAnalysis computes survival odds ratios from registry data using pandas; GRADE grading scores evidence as moderate for anticoagulation risks.
Synthesize & Write
Synthesis Agent detects gaps in lesion-specific models post-Roosevelt registry, flags contradictions between warfarin vs. heparin outcomes. Writing Agent uses latexEditText for guideline tables, latexSyncCitations linking Elkayam (2005), and latexCompile for reports; exportMermaid diagrams risk stratification flows.
Use Cases
"Extract heart failure incidence rates from ROPAC for VHD patients and plot by trimester."
Research Agent → searchPapers('ROPAC valvular heart disease') → Analysis Agent → readPaperContent(Ruys 2013) → runPythonAnalysis(pandas/matplotlib incidence plot) → researcher gets trimester-specific HF bar chart with GRADE scores.
"Draft ESC guideline summary on prosthetic valve anticoagulation in pregnancy with citations."
Synthesis Agent → gap detection('anticoagulation VHD pregnancy') → Writing Agent → latexEditText(draft) → latexSyncCitations(Elkayam 2005, Roos-Hesselink 2012) → latexCompile → researcher gets PDF guideline table.
"Find analysis code for pregnancy risk models in congenital heart disease papers."
Research Agent → paperExtractUrls(Balcı 2014) → paperFindGithubRepo → githubRepoInspect(R logistic models) → researcher gets Python scripts for CARP-II risk calculator adapted to VHD.
Automated Workflows
Deep Research workflow scans 50+ papers via searchPapers on 'VHD pregnancy outcomes', structures ROPAC/ESC reports with GRADE tables (Roos-Hesselink 2012). DeepScan's 7-steps verify anticoagulation contradictions: readPaperContent(Elkayam 2005) → CoVe → runPythonAnalysis(odds ratios). Theorizer generates hypotheses on surgical timing from Ávila (2003) patterns.
Frequently Asked Questions
What is valvular heart disease management in pregnancy?
It covers anticoagulation, surgical timing, and lesion-specific risks for VHD patients with native or prosthetic valves (Elkayam & Bitar, 2005).
What are key methods in this subtopic?
Registry-based analysis (ROPAC, ESC; Roos-Hesselink et al., 2012; Ruys et al., 2013) and risk prediction models (CARP-II; Balcı et al., 2014) assess maternal-fetal outcomes.
What are landmark papers?
Roos-Hesselink et al. (2012; 446 citations) from ESC registry; Elkayam & Bitar (2005; 277 citations) on valve-specific risks; Ávila et al. (2003; 269 citations) with 1,000 cases.
What open problems persist?
Optimal anticoagulation (warfarin vs. heparin), prospective VHD risk models, and gestational surgical thresholds lack RCTs (Ruys et al., 2013; Mehta et al., 2020).
Research Cardiovascular Issues in Pregnancy with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Valvular Heart Disease Management in Pregnancy with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers